Prism Research and MD Biosciences Receive First Contract Award as Members of the Minnesota Clinical Research Hub (MCRH)

MINNEAPOLIS--(BUSINESS WIRE)-- Minnesota Clinical Research Hub (MCRH) today announced its first contract for a multi-site, Phase I clinical research study. The contract was awarded to Prism Research and MD Biosciences, both based in St. Paul, MN and two of MCRH’s founding members.

Prism and MD Biosciences will provide comprehensive clinical trial execution and management, central laboratory services and biomarker testing to a leading European plasma biotherapeutics company seeking to obtain FDA approval for a vaccine currently available in Europe.

MCRH is a partnership of five Minnesota health industry leaders, collaborating to provide a comprehensive clinical trial platform, making it easier for life science companies and clinicians to bring lifesaving and life improving products to patients in need. In concert with local clinicians, Prism Research, MD Biosciences, Center for Diagnostic Imaging, Medtronic and ThreeWire provide sponsors with a seamless, customizable, yet flexible platform for conducting clinical trials.

“Minnesota has always possessed the critical assets required to be a significant contributor in pharmaceutical development,” said Geoff Grassle, MCRH Partner. “This contract will be the first of many opportunities for MCRH partners to leverage the expertise of local clinicians and MCRH members to expand Minnesota’s recognition as an international destination for clinical innovation.”

About Prism Research: Prism Research is a 52-bed clinical research company specializing in the execution and management of phase 1/2a studies in patient and healthy populations with an emphasis on complex study designs. Since 2005, Prism Research has provided FDA approved investigational pharmaceutical and medical device testing services for drug and device manufacturers, academic institutions and private physicians as well as other researchers across Minnesota, the U.S. and abroad. Further information is available at www.prismresearchinc.com.

About MD Biosciences: MD Biosciences is a pharmaceutical, biotechnology and diagnostics development company providing research services and advanced diagnostic capabilities to the clinical and pre-clinical research markets. As a CLIA-certified diagnostic laboratory, MD Biosciences offers a wide array of molecular, proteomic and cellular analysis across multiple sample types with biomarker experts experienced in the development and validation of custom fit-for-purpose assays. With an emphasis on inflammation, immunology, neurology, metabolic disease and pain, MD Biosciences supports the design, development and implementation of diagnostic tests for patient selection and stratification. Further information is available at www.mdbiosciences.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005183/en/